We investigated the role of angiotensin II in vascular and circulating inflammatory markers in spontaneously hypertensive rats (SHR). To this end, aortic mRNA expression of IL-1 , IL-6 and TNF-, as well as plasma levels of IL-1 , IL-6 and TNF-were measured in adult SHR untreated or treated with either the AT 1 receptor antagonist, candesartan (2 mg/Kg/d), or antihypertensive triple therapy (TT: hydralazine+hydrochlorothiazide+reserpine;20 + 7 + 0.15 mg/kg/d) for 10 weeks. Likewise, the aortic expression of NF B p50 subunit precursor, p105, and its inhibitor (I B) were measured. Wistar Kyoto rats of the same age were used as a normotensive reference group. High blood pressure levels were associated with an increase (p<0.05) in aortic mRNA expression of IL-1 , IL-6 and TNF-. Hypertension was also accompanied by an increase in plasma levels of both IL-1 and IL-6. No differences were observed in circulating levels of TNF-between SHR and WKY. SHR presented elevated aortic mRNA expression of the transcription factor NF B, and a reduction in its inhibitor I B.
INTRODUCTION
Hypertension is a primary risk factor for atherosclerosis. The intrinsic mechanisms by which elevated arterial pressure levels lead to atherosclerosis are not totally established, although mechanical stress and subsequent endothelial dysfunction have been involved (15, 25, 33) . Endothelial dysfunction has been mainly characterized by impaired endotheliumdependent relaxations (27, 31, 35) . Reduced availability of nitric oxide (NO) due to a diminution of its synthesis and/or enhanced degradation by superoxide anions has been implicated as a major cause of endothelial dysfunction in hypertension (5, 16, 31, 37) . In addition, an increase in the production of cytokines and other mediators of inflammation has been associated with endothelial dysfunction (11, 20) . It is known that inflammation plays a key role in the development of atherosclerosis, which is considered a chronic inflammatory disease (3) . However, the relationship between inflammation and hypertension is not well established because the effect of high blood pressure on inflammatory markers is not well determined. This is due to the variety of markers measured in the different studies, the origin (local or circulating) of the markers, as well as to contradictory results reported in different studies (2, 17, 21, 23, 26, 32) . In addition, the concomitant presence of other cardiovascular risk factors such as obesity, age and diabetes could have increased inflammation, and in turn been responsible for this variety of results (9, 21) .
Angiotensin II, the main active component of the renin-angiotensin system, plays an important role in the functional and vascular alterations associated with hypertension.
Furthermore, the administration of either angiotensin converting enzyme inhibitors or angiotensin II type-1 receptor antagonists is able to improve endothelial dysfunction and vascular remodeling in clinical and experimental hypertension (7, 14, 27, 28, 31) . In addition, angiotensin II is considered a proinflammatory mediator that plays a pivotal role in the inflammatory process underlying development and complications of atherosclerosis (4,24).
This role involves activation of transcription factors such as nuclear factor B (NF B), which participates in the regulation of numerous inflammatory factors including cytokines, chemokines, and adhesion molecules (4, 18, 29) . However, whether or not angiotensin II is involved in the inflammatory response associated with hypertension is not well established.
Therefore, the aim of this study was to investigate: 1) the role of angiotensin II in vascular and circulating inflammatory markers in spontaneously hypertensive rats (SHR), 2) the possible involvement of NF B/I B system in the effect of angiotensin II on inflammatory mediators in SHR. To this end, we studied aortic mRNA expression of interleukin 1 (IL-1 ), interleukin-6 (IL-6) and tumor necrosis factor (TNF-) and plasma levels of IL-6, IL-1 , and TNF-in SHR untreated or treated with AT 1 receptor antagonist candesartan. In addition, we evaluated the mRNA expression of NF B p50 subunit precursor, p105 (30), as well as of its inhibitor (I B) in aorta from the same rats. In order to elucidate whether the changes produced by candesartan could be due to blood pressure reduction or AT 1 receptor blockade, we examined the same parameters in SHR treated with the antihypertensive triple therapy (TT) of hydralazine+hydrochlorothiazide+reserpine. A group of Wistar Kyoto rats (WKY) were used as normotensive reference.
METHODS
Studies were performed in male SHR (20-22 weeks old; n=24) from Harlam Interfauna Ibérica (Barcelona, Spain). Animals were fed a standard chow (A=04; Panlab, Barcelona, Spain) and had free access to drinking water. Animals were treated with either vehicle, candesartan (2 mg/Kg/d; AstraZeneca,Goteborg, Sweden) or TT (hydralazine + hydrochlorothiazide + reserpine; 20 + 7 + 0.15 mg/kg/d) for 10 weeks given in the drinking water. The dose of candesartan and TT were chosen from previously published studies and adjusted to induce a comparable decrease in blood pressure (24, 36) . Wistar Kyoto rats (WKY; n=8) of the same age were used as a normotensive reference group. At the end of the treatment, systolic arterial pressure was measured by a tail-cuff pletysmograph (Narco BioSystems, Houston,TX) as previously described (28). On the day of the experiment, animals were killed by decapitation and blood collected in prechilled glass tubes containing EDTA.
Aorta was isolated for molecular biology determinations. Isolation and manipulation of aorta were always performed under sterile conditions. All experimental procedures were approved by the Animal Care and Use Committee of Universidad Complutense, according to the guidelines for ethical care of experimental animals of the European Union.
Plasma cytokine levels
Plasma IL-1 , IL-6 and TNF-were measured using quantitative sandwich enzyme immunoassay. A rat-specific monoclonal antibody of either IL-1 , IL-6 or TNF-, respectively, were pre-coated onto microplates (R&D Systems, Minneapolis, MN). The minimum detectable dose of either IL-1 or TNF-was 5 pg/ml and 10 pg/ml in the case of IL-6, with standard curve ranges for both IL-1 and IL-6, and for TNF-O, respectively, being (3.9-2000 pg/ml), and (12.5-800 pg/ml).
RNA isolation
Frozen rat aortas were pulverized in liquid nitrogen and homogenized together with 1 ml of Tri Reagent. RNA isolation was performed according to Chomczynski method (10).
RNA was quantified by optical density measurement at 260 nm using a BioPhotometer (Eppendorf, Germany). RNAs were frozen at -20ºC until used.
Reverse Transcriptase for cDNA synthesis
Five Rg of total RNA was taken to perform Reverse Transcriptase. It was previously heated with 2RM Random Hexamer at 70ºC for 5 minutes and quickly chilled on ice.
Subsequently, a mixture of RNase Inhibitor 0.7U, 25 mM Tris-HCl (pH 8.3), 37 mM KCl, 1.5 mM MgCl 2 , 10 mM DTT, dNTP's 0.4mM each and 2.5U of MMLV RT was added and incubated at 37ºC for 60 minutes followed by heating at 95ºC for 10 minutes and chilling on ice. Then, the mixture was completed with Dnase-free water until a final volume of 50 Rl.
Multiplex Polymerase Chain Reaction (MPCR)
Five Rl of above mentioned cDNA was taken for a MPCR reaction (MPCR Kit for Rat Inflammatory Genes Set-2, Maxim Biotech, Inc. San Francisco, CA). A Mixture of MPCR Buffer, Taq DNA Polymerase (2.5 U) and specific MPCR Primers for IL-6, IL-1 , TNF-, F B p50 subunit, I B and GADPH was added. The following time-temperature profile was used to perform MPCR: 2 cycles of 96º C, 1min and 58-60ºC, 2 min; 27 cycles for amplification of IL-1 , p105, I B and GAPDH genes and 32 cycles for IL-6 and TNF-of 94º C, 1 min and 58-60ºC, 2 min; 1 cycle of 70ºC,10 min and a final step of 25ºC.
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MPCR DNA product was fractioned electrophoretically on a 2% agarose gel containing 0.5 mg/ml ethidium bromide. The amplicon size of the genes were 532 bp for GAPDH, 453 bp for IL-6, 396 bp for p105, 351 bp for TNF-, 294 bp for IL-1 , 167 bp for I B. Band intensity was measured using a Gel Analysis Software (Syngene, Cambridge, UK). Data were normalized with GAPDH intensity data.
RESULTS
As shown in table 1, SHR presented higher systolic arterial pressure levels than WKY rats (p<0.05). Treatment with both candesartan or TT markedly reduced systolic arterial pressure to levels that were not different between both treatments. All groups presented similar body weight at the end of the experiment (table 1) .
Plasma levels of IL-6 and IL-1 were higher (p<0.05) in SHR as compared with control animals (Fig 1) . Both candesartan and TT reduced plasma levels of both IL-1 and IL-6 in SHR, this effect being more marked with candesartan than with TT. In fact, plasma levels of both cytokines were significantly lower in candesartan-treated rats as compared with those receiving TT. Neither hypertension nor treatments modified plasma levels of TNF-. mRNA expression of either IL-6, IL-1 or TNF-in aorta homogenates was higher in SHR as compared with WKY (Fig. 2) . Both candesartan treatment and TT reduced the increase in mRNA expression of the three cytokines in hypertensive animals (Fig.2) this reduction being more marked in the case of candesartan. Indeed, mRNA expression of the three cytokines was significantly lower in candesartan-treated animals than in TT-treated.
Hypertension also increased the aortic mRNA expression of p105, the NF B p50 subunit precursor, because levels were higher in SHR than WKY (Fig 3) . Candesartan but not TT was able to reduce it (Fig. 3) . By contrast, expression of the NF B inhibitor, I B, was reduced in aorta from SHR as compared with WKY. Candesartan increased I B expression to the same extent as TT treatment.
DISCUSSION
The present data show that SHR presented an elevated aortic expression of cytokines (IL-6, IL-1 and TNF-) as compared with WKY, suggesting an inflammatory process in the vascular wall associated with hypertension. This elevated vascular cytokine expression was accompanied by increased plasma levels of both IL-6 and IL-1 . The inflammatory process appears to be mediated by angiotensin II as well as an increase in hemodynamic forces associated with hypertension through the up-regulation of NF -B, as well as a down regulation of its inhibitor I -B.
The present study demonstated that high arterial pressure is associated with an inflammatory process in the vascular wall because aorta from SHR show an increase in the mRNA expression of IL-6, IL-1 and TNF-. Similarly, an increase in other markers of inflammation, including ICAM, VCAM, MCP-1 and IL-6 have been reported in vessels of hypertensive rats (17, 19, 21, 34) . This inflammatory process can play a key role in the progression of vascular damage associated with hypertension and could lead to the development of atherosclerosis, which is considered a chronic inflammatory disease (3). In addition, the elevated vascular expression of cytokines was accompanied by high circulating concentrations of IL-6 and IL-1 . Therefore, these data could suggest that hypertension is associated with a generalized inflammatory process since circulating levels may be generated from a variety sources, including not only the vascular wall but also extravascular ones such as adipose tissue and blood cells (1, 6) .
Mechanisms underlying the stimulation of both vascular and circulating inflammatory markers are not well established, although the participation of mechanical stress associated with hypertension can be suggested. This affirmation is based on the fact that reduction in either plasma concentrations or mRNA expression of inflammatory markers induced by both candesartan and TT was accompanied by a decrease in blood pressure. Therefore, these data supports the notion that the stimulation of mechanoreceptors by elevated arterial pressure is involved in the inflammatory process observed in SHR. However, although both treatments produced a similar decrease in blood pressure, the effect on inflammatory markers was bigger in candesartan-treated rats than in animals receiving an antihypertensive TT therapy which does not directly interact with AT 1 receptors (36). Consequently, mechanical stress reduction seems not to be the only mechanism accounting for improvement in the inflammatory process induced by candesartan. The participation of angiotensin II through AT 1 receptors in the inflammatory process associated with hypertension can, therefore, be proposed.
Supporting this concept is the observation made by Tummala et al. showing that the infusion of angiotensin II, but not of norepinephrine, for 6 days in rats induced an increase in VCAM-1 mRNA expression, although animals from both groups presented similar high BP levels (34).
Likewise, it has been shown that the administration of an AT 1 receptor antagonist, but not a diuretic, decreased VCAM-1 and MCP-1 in hypertensive patients (26) . Similarly, the inhibition of ACE or AT 1 receptor antagonism reduces the inflammatory phenotype in the vessel wall in LNAME-hypertensive rats (17, 21) . In consequence, both the blockade of AT 1 receptors as well as a mechanical stress reduction, seem to be mechanisms accounting for improvement in the inflammatory process induced by candesartan.
Numerous studies have shown that NF B participates in the vascular, renal and cardiac inflammatory processes observed in several non-genetic models of hypertension through its ability to activate a variety of inflammation-mediating genes (17, 18, 22, 34) . The present data show that the increase in inflammatory mediators observed in SHR was associated with a higher aortic mRNA expression of the NF B than in normotensive rats and a smaller expression of I B, which inhibits the translocation of NF B to the nucleus and consequently its activation. Therefore, the results suggest that a higher activation of NF B system is involved in the stimulation of inflammatory markers observed in SHR. This concept is further supported by the fact that the inflammatory marker decrease induced by both treatments was accompanied by an increase in the expression of the inhibitor I B.
Furthermore, the changes in I B expression observed in SHR seem to be mainly due to an increase in mechanical stress because both treatments not only prevent the changes to a similar extent, but also reduce blood pressure in a comparable manner. In addition, the role of angiotensin II is also apparent in the changes in NF B system observed in SHR. This participation is supported by the fact that candesartan, but not TT, partially prevented the upregulation of NF B although both similarly reduced blood pressure. Moreover, this effect was accompanied with a larger reduction in inflammatory markers in candesartan-treated than TT group. Similarly, NF B has been involved in the proinflammatory action of angiotensin II in 9 other models of hypertension in rats. In this regard, it has been reported that an angiotensin converting enzyme inhibitor reduced the expression of several inflammatory mediators in the aorta of LNAME-hypertensive rats. This reduction was accompanied by a minor activity of NF B (16). Likewise, the inhibition of NF B is able to ameliorate the renal and vascular inflammatory process in rats with angiotensin-II-induced hypertension (22).
In summary, the present results show that in rats, hypertension is associated with an inflammatory vascular process that can be one of the mechanisms by which elevated blood pressure levels lead to atherosclerosis. Angiotensin II, in addition to hemodynamic changes 
